Pregnancy Trimester, First

• 

  Subject Areas on Research

  • A new abortion technique: intravaginal and intramuscular prostaglandin. 
  • A prospective study of risk factors for first trimester miscarriage in Asian women with threatened miscarriage. 
  • Accuracy of reporting bleeding during pregnancy. 
  • Antimüllerian hormone as a risk factor for miscarriage in naturally conceived pregnancies. 
  • Association between first-trimester vaginal bleeding and miscarriage. 
  • Association of maternal serum progesterone in early pregnancy with low birth weight and other adverse pregnancy outcomes. 
  • Cell-free DNA analysis for noninvasive examination of trisomy. 
  • Cervical priming prior to dilatation and evacuation: a comparison of methods. 
  • Cervical priming prior to first-trimester suction abortion with a single 15-methyl-prostaglandin F2 alpha vaginal suppository. 
  • Characteristics of uterine activity in gestations less than 20 weeks. 
  • Comparison of gestational age at birth based on last menstrual period and ultrasound during the first trimester. 
  • Complications of prenatal therapy with diethylstilbestrol. 
  • Cyclophosphamide for lupus during pregnancy. 
  • Cytogenetics and mechanisms of spontaneous abortions: increased apoptosis and decreased cell proliferation in chromosomally abnormal villi. 
  • Cytokine expression by first-trimester human chorionic villi. 
  • Detection of Changes in Cervical Softness Using Shear Wave Speed in Early versus Late Pregnancy: An in Vivo Cross-Sectional Study. 
  • Early first trimester fetal dose estimation method in a multivendor study of 16- and 64-MDCT scanners and low-dose imaging protocols. 
  • Early first-trimester fetal radiation dose estimation in 16-MDCT without and with automated tube current modulation. 
  • Early pregnancy insulin resistance and subsequent gestational diabetes mellitus. 
  • Early risk factors for pregnancy loss in lupus. 
  • Epidemiologic and genetic aspects of spina bifida and other neural tube defects. 
  • Expectant management versus elective curettage for the treatment of spontaneous abortion. 
  • Factors associated with substance use during pregnancy: results from a national sample. 
  • First trimester fetal cardiac activity. Sonographic documentation of a progressive early rise in heart rate. 
  • First trimester insulin resistance and subsequent preeclampsia: a prospective study. 
  • First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. 
  • First trimester screening. 
  • First-trimester C-reactive protein and subsequent gestational diabetes. 
  • First-trimester and second-trimester screening at a community hospital: experience from the first year of implementation. 
  • First-trimester human chorionic villi express both immunoregulatory and inflammatory cytokines: a role for interleukin-10 in regulating the cytokine network of pregnancy. 
  • First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. 
  • First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. 
  • Hormone release and abortifacient effectiveness of a newly developed silastic device containing 15-ME-PGF2alpha methyl ester in concentrations of 0.5% and 1.0%. 
  • How can we better predict the risk of spontaneous miscarriage among women experiencing threatened miscarriage? 
  • Hydroxychloroquine in lupus pregnancy. 
  • Hyperemesis gravidarum complicated by Wernicke's encephalopathy. 
  • Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. 
  • Insulin resistance but not inflammation is associated with gestational hypertension. 
  • Luteolytic and abortifacient effects of serial intramuscular injections of 15(S)-15-methyl-prostaglandin F2alpha in early pregnancy. 
  • Maternal influences on nausea and vomiting in early pregnancy. 
  • Mid-trimester abortion induced by intravaginal administration of prostaglandin E2 suppositories. 
  • Midtrimester abortion induced by serial intramuscular injections of 15(S)-15-methyl-prostaglandin E2 methyl ester. 
  • Modelling the incremental benefit of introducing malaria screening strategies to antenatal care in Africa. 
  • Obesity and preeclampsia: the potential role of inflammation. 
  • Patterns and predictors of vaginal bleeding in the first trimester of pregnancy. 
  • Predicting gestational diabetes: choosing the optimal early serum marker. 
  • Predictors of vaginal bleeding during the first two trimesters of pregnancy. 
  • Prenatal diagnosis of Pompe's disease (type II glycogenosis) in chorionic villus biopsy using maltose as a substrate. 
  • Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study. 
  • Psychological responses after abortion. 
  • Religious beliefs affect grieving after pregnancy loss. 
  • Renal agenesis after first trimester exposure to chlorambucil. 
  • Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. 
  • Self-reported vitamin supplementation in early pregnancy and risk of miscarriage. 
  • Serial intramuscular injections of 15(S)-15-methyl-prostaglandin F2alpha in the induction of abortion. 
  • Spontaneous pregnancy reaches viability after low first trimester serum progesterone: a case report. 
  • The abortifacient effectiveness and plasma prostaglandin concentrations with 15(S)-15-methyl prostaglandin F2alpha methyl ester-containing vaginal silastic devices. 
  • The abortifacient effects of a newly developed vaginal silastic device impregnated with an 0.5% concentration of 15(S)-15-methyl-prostaglandin F2alpha methyl ester in the first trimester. 
  • The effect of a 10 cm2, 0.5% 15-ME-PGF2alpha methyl ester intravaginal silastic device on abortion and plasma prostaglandin concentration. 
  • The effect of cigarette smoke extract on trophoblast cell viability and migration: the role of adrenomedullin. 
  • The role of a long-acting vaginal suppository of 15-ME-PGF2 alpha in first and second trimester abortion. 
  • Threatened miscarriage and depressive and anxiety symptoms among women and partners in early pregnancy. 
  • Thrombosis during pregnancy and the postpartum period. 
  • Validation of serum progesterone <35nmol/L as a predictor of miscarriage among women with threatened miscarriage.